Top Story

FDA grants fast track status to Cometriq for advanced renal cell carcinoma

April 9, 2015

The FDA granted fast track status to cabozantinib for the treatment of patients with advanced renal cell carcinoma who have received one prior therapy, according to a press release from the drug’s manufacturer.

Cabozantinib (Cometriq, Exelixis) inhibits the activity of MET, VEGF receptors and RET tyrosine kinases, which are involved in normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and tumor microenvironment maintenance.

Jorge J. Castillo, MD In the Journals

Waldenström’s macroglobulinemia increases risk for secondary malignancies

March 25, 2015
Patients with Waldenström’s macroglobulinemia demonstrated an increased risk for secondary malignancies compared with the general population, according to…
In the Journals

Pediatric germ cell tumor incidence varied by gender, age; survival high

March 16, 2015
The localization and histology of pediatric germ cell tumors varied between genders and age groups, with an increased incidence rate observed only in ovarian germ cell…
Adolescents and young adults with cancer have not experienced the same survival gains as children, according to Michael P. Link, MD, professor of pediatrics at Stanford University School of Medicine. “If you look at virtually every disease that we treat, once somebody hits 10 years of age, the prognosis gets worse,” Link said. Cover StoryPerspectivePublication Exclusive

Clinicians strive to meet needs of ‘underserved’ AYA population

HemOnc Today, March 10, 2015
Adolescents and young adults with cancer historically have fallen through the cracks between pediatric and adult oncology practices.Approximately 70,000 adolescent and…
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
Meeting News Coverage Video
Recurrent themes of ASCO: Money and molecules

Recurrent themes of ASCO: Money and molecules

June 7, 2013
CHICAGO — Donald L. Trump, MD, FACP, president and CEO of Roswell Park Cancer Institute, offers his insights on…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
FDA News

FDA grants fast track status to Cometriq for advanced renal cell carcinoma

April 9, 2015
The FDA granted fast track status to cabozantinib for the treatment of patients with advanced renal cell carcinoma who have received one prior…
Jorge J. Castillo, MD In the Journals

Waldenström’s macroglobulinemia increases risk for secondary malignancies

March 25, 2015
Patients with Waldenström’s macroglobulinemia demonstrated an increased risk for secondary malignancies compared with the general…
In the Journals

Pediatric germ cell tumor incidence varied by gender, age; survival high

March 16, 2015
The localization and histology of pediatric germ cell tumors varied between genders and age groups, with an increased incidence rate observed only in…
Adolescents and young adults with cancer have not experienced the same survival gains as children, according to Michael P. Link, MD, professor of pediatrics at Stanford University School of Medicine. “If you look at virtually every disease that we treat, once somebody hits 10 years of age, the prognosis gets worse,” Link said. Cover StoryPerspectivePublication Exclusive

Clinicians strive to meet needs of ‘underserved’ AYA population

HemOnc Today, March 10, 2015
Adolescents and young adults with cancer historically have fallen through the cracks between pediatric and adult oncology practices.Approximately…
FDA News

FDA fast tracks HS-410 for nonmuscle-invasive bladder cancer

March 9, 2015
The FDA today granted fast track designation to HS-410 for use in combination with Bacillus Calmette-Guérin immunotherapy for the treatment…
Naomi B. Haas, MD Meeting News Coverage

VEGF inhibitors not effective for locally advanced kidney cancer

February 24, 2015
Although the VEGF inhibitors sorafenib and sunitinib are widely used and typically effective in the treatment of metastatic kidney cancer, use of the…
In the Journals

Extra-virgin olive oil ingredient rapidly induces cancer cell death

February 19, 2015
Oleocanthal, an ingredient found in extra-virgin olive oil, induces cancer cell death without harming noncancerous cells, according to study…
thumbnail for video 4040847621001 Video

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and HemOnc Today's Chief…
In the Journals

Large retroperitoneal lymphadenopathy predicted VTE risk in disseminated germ cell tumors

February 5, 2015
Large retroperitoneal lymph nodes demonstrated greater discriminatory accuracy than a high-risk Khorana score for the prediction of risk for…
Toni K. Choueiri, MD In the Journals

PD-L1 expression, CD8+ T-cell counts associated with shorter OS in mRCC

January 28, 2015
Higher levels of PD-L1 expression, as well as PD-L1 expression plus tumor CD8+ T-cell counts, were linked to shorter survival in patients with…
More Headlines »
morganatic-roan
morganatic-roan